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The purinergic P2X7 receptor (P2X7R) plays an important role during the immune response, participating in several events such
as cytokine release, apoptosis, and necrosis. The bacterial endotoxin lipopolysaccharide (LPS) is one of the strongest stimuli of the
immune response, and it has been shown that P2X7R activation can modulate LPS-induced responses. Moreover, a C-terminal
bindingsiteforLPShasbeenproposed.InordertoevaluateifLPScandirectlymodulatetheactivityoftheP2X7R,wetestedseveral
signaling pathways associated with P2X7R activation in HEK293 cells that do not express the TLR-4 receptor. We found that LPS
alonewasunabletoinduceanyP2X7R-relatedactivity,suggestingthattheP2X7Risnotdirectlyactivatedbytheendotoxin.Onthe
other hand, preapplication of LPS inhibited ATP-induced currents, intracellular calcium increase, and ethidium bromide uptake
and had no eﬀect on ERK activation in HEK293 cells. In splenocytes-derived T-regulatory cells, in which ATP-induced apoptosis is
driven by the P2X7R, LPS inhibited ATP-induced apoptosis. Altogether, these results demonstrate that LPS modulates the activity
of the P2X7R and suggest that this eﬀect could be of physiological relevance.
1.Introduction
T h eP 2 X 7r e c e p t o r( P 2 X 7 R )i sam e m b e ro ft h ef a m i l yo f
nonselective cationic channels gated by extracellular ATP,
termed P2X receptors. This receptor has unique properties
with respect to other P2X members, like its low aﬃnity
for ATP and its ability to be activated in murine cells by
ADP-ribosylation through ADP-ribosyltransferase (ARTs)
and nicotinamide adenine dinucleotide (NAD) [1, 2]. Unlike
otherP2XRs,theP2X7Rformsamacroporewhenexposedto
continuous or high-level applications of ATP that allows the
passage of 900-Da molecules (as Lucifer Yellow) which often
induces cell death (reviewed in [3, 4]). This process seems
to involve both dilation of the channel pore and opening2 Mediators of Inﬂammation
of additional channels, such as pannexin-1 [5]. Although
P2X7R expression has been detected in various tissues,
including neurons, glial cells, ﬁbroblasts, smooth muscle,
and endothelial and epithelial cells (reviewed in [4]), it is
in immune cells, such as monocytes, macrophages, dendritic
cells, and T cells, where P2X7R function has been more
extensively studied [6]. This receptor is a crucial player for
induction of inﬂammatory responses in vivo. For instance,
the use of P2X7R antagonists abolishes the development of
inﬂammatory response to LPS. P2X7R knock-out mice show
lower mortality and proinﬂammatory cytokine production
under systemic LPS challenge than wild-type animals [7].
MolecularmechanismsassociatedwiththeP2X7Rininﬂam-
mation are linked to inﬂammasome activity including a role
intheinduction,maturation,anddeliveryofIL-1β(reviewed
in [8, 9]). Under several pathophysiology conditions, such
as cell necrosis, in vivo inﬂammatory responses, and in
tissue trauma, NAD, ATP, and metabolites are released and
reach extracellular concentrations that can activate P2X7Rs
and promote cell death [2]. Therefore, immune cells that
express P2X7R respond during inﬂammatory events. In
this context, molecules that can regulate P2X7R activity,
such as LPS, could also have a key regulatory role during
these events. Similar eﬀects have been proposed for other
P2X7Rmodulatorslikedivalentcations[10,11],endogenous
lipids, and hydrophobic compounds. For example, lysophos-
phatidylcholine potentiates Ca2+ inﬂux, apoptosis, and ERK
activation in mouse microglial cells [12]; PIP2 induces
a positive modulation in P2X7R currents [13]; BSA, 11-
((5-dimethylaminonaphthalene-1-sulphonyl)amino) unde-
canoic acid (DAUDA) and arachidonic acid (AA) markedly
increases BzATP potency and stimulates ethidium accumu-
lation [14]. AA also induces a robust increase in ERK1/2
phosphorylation when coapplied with BzATP, whereas no
diﬀerences are observed in other MAPKs [15]. Polymyxin
B and speciﬁcally its hydrophobic tail positively modulate
P2X7R-mediated ethidium uptake [16]. Similarly, a diverse
range of lipids increases agonist potency in the P2X7R
in functional and binding studies [17]. P2X7R agonists
alone can stimulate PLA2-mediated arachidonic acid release,
and the antagonist OATP inhibits this eﬀect [18]. In
P388D1 murine macrophages, inhibition of the P2X7R
attenuates LPS-stimulated prostaglandin production, which
is correlated with reduced soluble PLA2 (sPLA2) activity
and a reduction in the transcriptional upregulation of
cyclooxygenase-2[19].Altogether,theseﬁndingssuggestthat
P2X7R regulation by lipids could be relevant in inﬂam-
mation. The idea that LPS modulates P2X7R activity was
suggestedbyDenlingeretal.[20],whoidentiﬁedaconserved
LPS-binding site in the C-terminal domain of the P2X7R.
Synthetic peptides derived from this domain can bind LPS
in vitro, leading to inhibition of LPS-induced ERK activation
in RAW 264.7 cells [20].
Our aim was to determine whether LPS may modu-
late P2X7R activation and if it is related to physiological
processes. We evaluated whether LPS can aﬀect ATP-gated
currents, intracellular calcium, ERK activation, and apop-
tosis in P2X7R-expressing HEK293 cells. This heterologous
system does not express TLR-4, the main function of which
is to identify the LPS of gram-negative bacterial cell wall
and activate the innate immune system [21]. We found that
LPSdiﬀerentiallymodulatesATP-inducedactivity,inhibiting
ATP-gated currents, intracellular calcium increases, and
ethidium bromide uptake, while having no eﬀect on ATP-
dependent ERK activation. LPS treatment also inhibits ATP-
induced apoptosis in CD4+ CD25+ regulatory T cells,
protectingthemfromcelldeath.Onthebasisoftheseresults,
we propose that LPS may have a role as a regulator of P2X7R
activity during inﬂammation.
2.ExperimentalProcedures
2.1. Animals, Cells, and Transfection of the P2X7 Receptor in
HEK293Cells. Maleandfemale6–8-week-oldC57BL/6mice
were obtained from the USACH Research Facility, with their
use approved by the Ethics Committee. Animals were euth-
anized by cervical dislocation, spleens were removed under
sterile conditions, and splenocytes were obtained discarding
erythrocytesbytreatmentwithACKbuﬀerlyses.Splenocytes
were cultured in RPMI 1640 medium (Invitrogen Corpo-
ration, Carlsbad, Calif, USA) supplemented with 10% FBS
(Biological Industries Ltd., Kibbutz Haemek 25115, Israel),
50U/mL penicillin-streptomycin, and 2.5μg/mL ampho-
tericin B (Sigma-Aldrich, St. Louis, Mo, USA). All salts used
were of analytical degree. Antibodies to CD4 and CD25 were
purchased from Santa Cruz Biotechnology (clones RM-4
and PC61, resp.). Antibody to CD8 was obtained from BD
Biosciences Pharmingen (San Diego, Calif). Regulatory T-
cell kit detection assay was obtained from eBioscience (San
Diego, Calif). Annexin V-FITC Apoptosis Detection Kit was
purchased from BD Biosciences Pharmingen.
HEK293 and U937 cells were cultured in DMEM
medium (Invitrogen Corporation, Carlsbad, Calif, USA)
supplemented with 10% FBS (Biological Industries Ltd.,
Kibbutz Haemek 25115, Israel), 50U/mL penicillin-
streptomycin, and 2.5μg/mL amphotericin B (Sigma-
Aldrich, St. Louis, Mo, USA). Rat P2X7R cloned into
pIRES2-eGFP was kindly donated by Dr. S. Stojilkovic
(NIH, Bethesda, Md, USA). Cells were transfected with
lipofectamine (Invitrogen Corporation, Carlsbad, Calif,
USA) following the manufacturer’s instructions. Stable
clones were isolated by G418 (EMD Biosciences, Inc, San
Diego, Calif, USA) selection under standard procedures, and
expression was evaluated routinely.
2.2. Electrophysiology. ATP-gated current was measured with
an AXOPATCH 200B ampliﬁer in whole cell conﬁguration
(Molecular Devices, Calif, USA), using standard patch-
clamp techniques. The composition of the pipette solution
was (mM): 140KCl, 5NaCl, 1MgCl2, 10EGTA, 10HEPES,
pH7.2. The bath solution contained (mM): 140NaCl, 5KCl,
1MgCl 2,1CaCl 2,10glucose,and10HEPES,pH7.4.Record-
ing pipettes had 4MΩ of resistance. Command voltage
protocols and acquisition were controlled by pCLAMP
10.2 (Molecular Devices, Calif, USA) through a laboratory
interface (Digidata 1322A, Molecular Devices, USA). Unless
otherwise shown, membrane holding potential (Vm)w a sMediators of Inﬂammation 3
−80mV. For ramp protocols, the holding potential was
0mV, following a 1-s voltage ramp from −120 to +120mV.
Currents were ﬁltered at 1kHz with an eight-pole Bessel
low-pass ﬁlter (Frequency Devices) and digitized at 5kHz.
The liquid junction potential between internal and external
solutions was estimated to be 3.7mV and was subtracted
from all records. All the experiments were performed at
room temperature; ATP was applied to the cells by a gravity
perfusion system. Data were analyzed with Clampﬁt 10.2
software (Molecular Devices, Calif, USA).
2.3. Intracellular Calcium Measurement. Intracellular cal-
cium was measured with using the cell-permeable calcium
indicator Indo-1AM or Fura-2AM. For Indo-transfected or
c o n t r o lH E K 2 9 3c e l l sw e r es e e d e da t1 0 5 cells on 35mm
coverslips. The following day, the cells were incubated with
5μM Indo 1-AM in bath solution for 1.5h in darkness. The
cells were then washed twice with PBS and incubated in
DMEM with serum for 1h in darkness. Single cells were
selectedandexcitedat360nm,andﬂuorescencewasdetected
with a photomultiplier at 405 and 488nm (Nikon). Only one
cell per coverslip was used for the experiment, and the bath
solutionswerethesameasforelectrophysiology.Thecalcium
signal was obtained at a ﬂuorescence ratio of 405/488nm.
2.4. Western Blots, RT-PCR, Ethidium Bromide Uptake, and
Apoptosis. For Western blot analyses, P2X7R-HEK293 cells
were seeded in 6-well plates or on 22-mm collagenized
coverslips. The plates were stimulated with 600μMA T P
(Sigma-Aldrich, St. Louis, Mo, USA), unless another con-
centration is indicated. LPS challenges were made using
0.1μg/mL LPS E. coli serotype 055:B5 (Sigma-Aldrich,
St. Louis, Mo, USA) incubated for diﬀerent times. Treat-
ments, methods, and antibodies used (except for anti-
P2X7), and data acquisition were as previously described
[22]. RNA extraction and RT-PCR and visualization of
P C Rp r o d u c t sw e r ed o n ea sp r e v i o u s l yd e s c r i b e d[ 23].
Ampliﬁcation of 16S was done using speciﬁc primers
(sense: 5 -GGGGTTTACGACCTCGATGTT-3  antisense: 5 -
GCTTTAAGTATGGGCCCCCCT-3 ); PCR conditions were
94◦C for 4min followed by 29 cycles of 94◦C for 40s, 50◦C
for 40s, and 72◦C for 20s. TLR-4 ampliﬁcation was done
using speciﬁc primers (sense CAACAAAGGTGGGAAT-
GCTT 317, antisense TGCCATTGAAAGCAACTCTG), with
PCR conditions 94◦C for 4min followed by 30 cycles of 98◦C
for 10s, 60 for 2min, 74 for 15s.
To determine ethidium uptake, semiconﬂuent P2X7R-
expressing HEK293 cells were incubated at 37◦C in PBS
nominally divalent cation-free buﬀer supplemented with 1%
ofFBS.After10minincubation,20μg/mLethidiumbromide
(Amresco Inc., Solon, Ohio) was added, and 1min later, the
cells were treated with ATP or LPS. The results were analyzed
by confocal microscopy (LSM 510) using a Plan-Neoﬂuar
objective (20x; 0.5 NA; Carl Zeiss, Inc.) every 15s for 30min,
withHeNelaserexcitationwitha560-nmlong-passemission
ﬁlterforethidiumbromide.ImageswerecollectedusingLSM
510 software (Carl Zeiss, Inc.).
To monitor induction of cell death, splenocytes were
preincubated 30 minutes with or without LPS, Brilliant
Blue G (Sigma-Aldrich, St. Louis, Mo, USA), or A740003
(Tocris Bioscience, Ellis-ville, Mo, USA) and challenged with
60μM ATP (Sigma-Aldrich) or, unless other conditions
are speciﬁed, in RPMI 1640 supplemented with 10% FBS,
50U/mL penicillin-streptomycin, and 2.5μg/mL ampho-
tericin B, and cells were evaluated after 24h of culture. Total
CD4+CD25+andfoxp3+populationswereevaluatedat24h
after challenge as previously described [24]. In parallel, cells
were recovered 3h after-treatment and stained to identify
CD4+ and CD4+ plus CD25+ cells with the Annexin V-
FITC Apoptosis Detection Kit I (BD Biosciences). Stained
cells were detected in a FACS Canto II (Becton Dickinson,
NJ USA).
2.5. Data Acquisition and Analysis. All protocols were per-
formed at least three times on two clones. ATP-induced
activation was evaluated in parallel with other protocols.
Point-to-point analysis was performed using the Kruskal
Wallistest,withaDunnposttest.Alldatawereanalyzedusing
GraphPad software (GraphPad software Inc, La Jolla, Calif,
USA) and are shown as average ± standard error (S.E.M).
Statistical diﬀerences were considered with P<0.05.
3. Results
3.1. Preapplied LPS Inhibits ATP-Evoked Currents in the
Presence of FBS. To determinate whether LPS induces direct
eﬀects or modulates the activity of the P2X7R, we used
HEK293 cells as an expression system. These cells do not
express detectable levels of messenger levels by PCR nor
protein on surface by ﬂow cytometry of the canonical LPS
receptor TLR-4 (see Figure S1 in supplementary material
available online at doi:10.1155/2011/152625). ATP evoked
dose-dependent inward cationic currents in stable P2X7R-
transfected HEK293 cells (P2X7R-HEK293), with an EC50
of 150 ± 58μM and a maximal current density of 18.4 ±
4.1pA/pF (n = 6). As shown in Figure 1, LPS alone
was unable to trigger currents (Figure 1(a)). Similarly, LPS
coapplication (Figure 1(a)) or preapplications as long as
30 minutes (not shown) had no eﬀect on ATP-induced
currents. As a ﬁrst screening of LPS-potential eﬀects, a
concentration of 300μM ATP was used, which is close to
EC50, allowing us to determine either positive or negative
eﬀects. Since LPS-related eﬀects have been shown to be
dependent of serum factors like LPS-binding protein (LBP)
[25], in subsequent experiments we evaluated the eﬀects
of LPS on ATP-induced currents, in the presence of 1%
FBS in the extracellular recording solution. The addition
of FBS increased the amplitude of ATP-induced currents
but had no eﬀect on ATP aﬃnity (EC50 = 169 ± 9μM;
Imax = 60 ± 6.1pA/pF, n = 8). As shown in Figure 1(b),
LPS reversibly inhibited the ATP-induced currents in a
time-dependent manner. The inhibition of the ATP-evoked
currentsafter10minofcontinuousLPSapplicationwas57 ±
9% (Figure 1(c)). We then tested LPS eﬀects along the entire
ATP concentration response curve. LPS displaced rightward
the curve, increasing ATP EC50 from 169 ± 9 to 375 ±
17μM( P<0.01, n = 8; Figure 1(d)). LPS inhibited the
ATP-induced response at all tested concentrations, reducing4 Mediators of Inﬂammation
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Figure 1: LPS inhibits ATP-induced currents in P2X7R-HEK293 cells. (a) LPS alone (1μg/mL) does not gate currents nor inhibit 300μM
ATP-gated currents when coapplied. Data are representative of 5-6 independent experiments, in the absence of FBS. (b) Representative
experimentoftheLPS-inducedinhibitionofATP-evokedcurrents.TheeﬀectofLPSistime-dependent,experimentswereruninthepresence
of 1% FBS. (c) Summary of the eﬀect of LPS on ATP-evoked currents after 1, 10, and 15min of preapplication (n = 6–8, P<0.05, Kruskal-
Wallis test). (d) ATP concentration-response curves in the absence (open circles) or in the presence of 1μg/mL LPS (closed circles). LPS was
added 30min before the start of each experiment (n = 5).
the maximal current density by 55%, from 60 ± 6.1 to
26 ± 3.9pA/pF (P<0.01, n = 8; Figure 1(d)). Next, we
evaluated if LPS inhibition was related with changes in the
reversal potential performing voltage ramps (Figure 2(a)). In
order to minimize receptor desensitization during ramps,
we used 300μM ATP (we used the same cells to perform
ramps in the absence and presence of LPS). LPS decreased
the ATP-induced currents at all voltages, with no changes
in the reversal potential (Erev = 6.8 ± 0.4a n d6 . 5±
0.2mV in control and LPS-treated cells, resp., Figure 2(a),
inset). This suggests that LPS treatment does not modify
the permeability of the channel. To determine the potential
role of Ca2+, its extracellular concentration was increased to
10mM (Figure 2(b)). Under these conditions, we did not
observe changes in reversal potential in cells treated with
LPS (Erev = 5.6 ± 0.8mV ; Figure 2(b), inset). Altogether,
these results suggest that LPS modulates the ATP-dependent
current when it is preapplied without modifying P2X7R
ionic permeability.
3.2. P2X7R-Mediated Calcium Inﬂux Is Inhibited by LPS
Treatment. Our next aim was to determine if the eﬀects
of LPS in P2X7R-mediated currents was also observed
in P2X7R-mediated calcium inﬂux. ATP induced a
concentration-dependent increase of intracellular calcium in
P2X7R-HEK293 cells (Figure 3(a)); this eﬀect was mimicked
by the speciﬁc P2X7R-agonist BzATP (Figure 3(a)). LPS-
mediated eﬀects were evaluated at a concentration that
induces a maximal response (600μM) and that mostly
desensitizes the potential responses by P2Y and adenosine
receptors. As observed in current recordings, LPS had no
eﬀect on ATP-evoked responses when FBS was not present
(Figure 3(b)). In the presence of 1% FBS, LPS inhibited
calcium increases evoked by 600μMA T P( Figure 3(b))Mediators of Inﬂammation 5
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Figure 2: LPS does not change the permeability of the P2X7R. (a)
Voltage-ramp protocols were applied with 300μMA T Pa l o n e( g r e y
line) or treated with 1μg/mL LPS (black line); the insert shows
a closeup of reversal potentials. Control and treated experiments
were performed in parallel and repeated independently 4 times.
(b) The same protocol was performed in the presence of 300μM
ATP (ATP), preincubated with LPS (ATP + LPS) with normal and
10mM extracellular calcium (A + L + 10mM Ca2+).
in a time-dependent manner, in similar fashion to that
observed in whole-cell currents (compare with Figure 1(b)).
The inhibition of the ATP-evoked transients attained after
7min of LPS application was 43 ± 9% (P<0.01, n = 5;
Figure 3(d)). In order to further discard the contribution
of endogenous P2Y and adenosine receptors, we used the
speciﬁc P2X7R-agonist Benzoyl-ATP (BzATP). A 7-min
application of LPS-inhibited BzATP-induced calcium
increases by 30% (Figure 3(e), n = 3). Finally, recordings
performed in the absence of extracellular calcium conﬁrmed
that the LPS eﬀects that we observed are speciﬁc to the
P2X7R; the endogenous responses were minimal compared
to the high calcium increases observed in HEK293-P2X7R
cells (Figure 3(f) and Suppl. Figure 2).
3.3. LPS Inhibits ATP-Induced Macropore and Apoptosis. We
next evaluated if LPS could aﬀect macropore formation.
1mM ATP induced the uptake of ethidium bromide (EtBr)
in the presence of 1% FBS. This concentration of ATP
was chosen because it has been described as inducing
maximal uptake. EtBr uptake was time-dependent, leading
to maximum incorporation at 25–30min (Figure 4(b)). In
contrast, no staining was observed in control (Figure 4(a))
or in cells treated with LPS alone (not shown). However,
LPS (preapplied for 30min) signiﬁcantly inhibited the ATP
induced EtBt uptake (P<0.05, Figures 4(a) and 4(b)). We
next tested the eﬀect of LPS at diﬀerent ATP concentrations;
Figure 4(c) shows that LPS consistently decreased EtBr
uptake at 10, 60, 100, and 1000μM ATP (assays were made
at 30min after the ATP challenge).
Because these results indirectly indicated that LPS
inhibits P2X7R-mediated apoptosis, we next used annexin V
(an apoptosis assay) to conﬁrm this. We decided to evaluate
apoptosis in cells that endogenously express P2X7R. To that
end, we used CD4+ CD25+ Treg lymphocytes, regulators
of the immune response derived from splenocytes. This cell
typehasbeendemonstratedtobemoresensitiveandtoshow
higher aﬃnity for ATP compared to other cells, including
conventional CD4 and CD8 cells. ATP-mediated eﬀects have
been demonstrated to be dependent on the P2X7R and at
concentrations as low as 60μM[ 24]. We ﬁrst determined the
eﬀects of ATP and LPS on the total splenocyte population.
Treg cell death was evaluated as depletion of Treg from total
splenocyte culture, after a 24h treatment with 60μMA T P ,i n
the presence of FBS. ATP induced 45 ± 5% depletion of Treg
cells (Figure 5(a)). LPS alone did not induce changes (not
shown); however, LPS preapplied at all concentrations tested
abolished ATP-induced depletion (Figure 5(a)). Splenocytes
include a variety of cell types, including some that are LPS-
sensitive, so our results cannot be related exclusively to
P2X7R inhibition (e.g., the pleiotropic increase in T-CD4+,
as shown in Figure 5(a): compare ﬁrst and last columns). In
order to discard nonspeciﬁc eﬀects, we evaluated the eﬀect
of acute LPS application on annexin V (AV) exposure as
a measure of P2X7R-mediated early apoptosis. Splenocytes
were pretreated for 30min with LPS and challenged with
ATP for 3h (in FBS-containing medium). After that, cells
were stained against CD4+, propidium iodine (PI), and AV
and evaluated by ﬂow cytometry. ATP induced a 47 ± 10%
increase in AV+ PI-population, indicating an increase in the
number of apoptotic cells (Figure 5(b)). No changes were
observed in double-positive population, indicating that this
eﬀect was related to apoptosis in the CD4+ population.
LPS alone did not induce any change; however, it abol-
ished the ATP-induced increase in the AV+ PI-population
(Figure 5(b)). To further conﬁrm the role of the P2X7R,
we used the speciﬁc antagonists Brilliant Blue G (BBG)
and A740003. These antagonists behaved similarly to LPS,
inhibiting the ATP-induced increase in AV+ PI-population
(Figure 5(b)). This pattern was also observed in the CD4+
CD25+ population (Figure 5(c)). Altogether, these results
suggest that LPS is able to protect to Treg cells from P2X7R-
mediated ATP-induced apoptosis.
3.4. LPS Does Not Modify the ATP-Induced ERK Activation.
Several signaling pathways are activated after P2X7R
stimulation [26–30], including the ERK pathway. Our
next aim was to determine if LPS-induced changes on6 Mediators of Inﬂammation
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Figure 3: LPS inhibits ATP-induced intracellular calcium increases in P2X7R-HEK293 cells. (a) Representative tracings of a single cell
responding to diﬀerent ATP concentrations and to 60μM of the P2X7R-agonist BzATP. (b) Representative recordings showing the lack of
eﬀects of LPS in the absence of FBS. (c) Representative recordings showing the time dependent inhibition of ATP-induced calcium transients
induced by 1μg/mL LPS, in the presence of 1% FBS. (d) Summary of the inhibition induced by 7min of LPS preapplication (P<0.01,
n = 4). (e) Recordings of calcium increases induced by 60μM BzATP and inhibition by the pre-application of LPS. Similar results were
observed in 3 diﬀerent cells. (f) Recordings in the absence of extracellular calcium, in the absence (black tracing), and in the presence (gray
tracing) of LPS (preapplied for 7min).
P2X7R-mediated ERK activation, since it has been
demonstrated that this eﬀect is independent of its channel
activity [31]. These authors described that in HEK293 cells,
ATP induces ERK activation in P2X7R expression but not
in mock cells [31]. In our case, we did not detect ATP-
induced ERK activation in nontransfected HEK293 cells
(data not shown), in agreement with Amstrup and Novak.
In P2X7R-expressing cells, ATP induced a time-dependent
activation of the ERK pathway (Figures 6(a) and 6(b))i n
the presence of FBS, with a maximum activation of 2–5min
afterstimulation, decreasing later, and then remaining stable
throughout the rest of the experiment (Figure 6(b)). Under
similar conditions, LPS alone was unable to trigger this eﬀect
(Figure 1(b) and Supp. Figure 3), suggesting that it is not
able to directly activate the ERK pathway in our cell system
and further supporting the absence of endogenous TLR-4
receptors in HEK293 cells. As a control and to test LPS
activity on the TLR-4 receptor, we observed a LPS activation
of ERK pathway in the macrophage cell-line Raw 264.7
(Supp. Figure 3). Higher LPS concentrations (10μg/mL)
also failed to induce ERK activation (data not shown). Next,
we preapplied LPS for 30min before ATP stimulation for
5min on P2X7R-HEK293 cells. Under these conditions,
LPS was unable to modify the ATP-induced changes inMediators of Inﬂammation 7
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Figure4:LPSinhibitstheATP-inducedEtBruptakeonP2X7R-HEK293cells.(a)RepresentativeimagesobtainedfromEtBruptakeprotocols
in nontreated cells (basal) after 30min of treatment with 1mM ATP alone (ATP) or plus 1μg/mL LPS (ATP + LPS). (b) Summary of the
time-dependent EtBr incorporation obtained with 1mM ATP alone (open circles) or plus LPS (closed triangles); n = 4. (c) LPS inhibition of
ATP-induced EtBr uptake at diﬀerent ATP concentrations (P<0.05, unpaired t-test; n = 3-4). Experiments were performed in the presence
of 1% FBS.
ERK activation (Figures 6(c) and 6(d)). Similarly, we did
not observe diﬀerences when ATP was applied for 15min
(Figure 6(d)). Altogether, these results demonstrate that in
o u rc e l ls y s t e m ,L P Sd o e sn o ta c ta sa na g o n i s to ft h eE R K
pathwayorasamodulatoroftheATP-inducedERKpathway.
4. Discussion
In this study, we determined that the pre-application of
LPS inhibits ATP-evoked currents, calcium inﬂux, and delays
macropore formation in P2X7R-HEK293 cells without mod-
ifying ERK activation. In the absenceof ATP, LPS is unable to
induce any response related to P2X7R activation, suggesting
that LPS acts as a receptor modulator. Additionally, we
observed inhibition of ATP-induced apoptosis in regulatory
Tc e l l sb yL P St r e a t m e n t ,e ﬀect that was reversed by a P2X7R
antagonist, suggesting that this phenomenon could be of
physiological relevance.
Using diﬀerent experimental approaches we consistently
found that LPS modulates processes related to the channel
activity of the P2X7R but not to ERK activation, a process
that has been proposed to be independent of P2X7R channel
activity. Ampstrup and Novak described that in P2X7R-
expressing but not in control HEK293, ATP is able to induce
ERKactivation[31].Moreover,thiseﬀectispreservedincells
expressing mutated receptors that do not exhibit channel
activity, suggesting that P2X7R can signal through multiple
pathways [31]. Accordingly, Garcia-Marcos et al. described
the existence of 2 receptor pools involved independently
in the P2X7R channel or signaling activity [32, 33]. These
authors suggested that lipid interactions with the P2X7R on
plasma membrane raft domains are important in deﬁning
its downstream response. It appears that receptors present
on rafts are exclusive for signal transduction (like ERK
phosphorylation), while nonraft P2X7Rs act mainly as ionic
channels (reviewed in [33]). In this context, it is possible that
LPS induces a relocalization of the P2X7R, decreasing the
pool of receptor’s able to be activated as channels.
The speciﬁc mechanism of LPS-induced inhibition of
P2X7R channel activity remains unclear; however, some8 Mediators of Inﬂammation
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Figure 5: LPS protects from ATP-induced depletion and apoptosis in CD4+ CD25+ T-regulatory cells. (a) LPS abolishes the ATP-induced
depletion of Treg’s population. ATP (60μM, gray bars) was applied for 30min, 24h before cell staining and ﬂow cytometry. ∗P<0.05,
Mann-Whitney test, n = 4. (b) Eﬀects of LPS (1μg/mL) and BBG (100nM, a P2X7R antagonist) in ATP-induced early apoptosis measured
with annexin V (AV) assay. ATP (60μM) was applied for 30min, 3h before cell staining and ﬂow cytometry. Open bars correspond to the
apoptotic population, whereas gray bars represent necrotic cells. ∗P<0.05, Mann-Whitney test, n = 4. (c) LPS and BBG inhibit the ATP-
induced increase in CD4+ CD25+, annexin-positive population. ATP was applied for 30min, 3h before cell staining and ﬂow cytometry.
∗P<0.05, Mann-Whitney test, n = 4.
plausible explanations consider the putative C-terminal LPS-
binding site (residues 573–590), originally described by
Denlinger et al. [20, 34]. This domain appears to be highly
functional given that peptides derived from this sequence
a r ea b l et ob i n dL P Sin vitro and inhibit LPS-induced
ERK activation in RAW 264.7 cells [20, 34]. It has been
suggested that this phenotype correlates with changes in
receptor traﬃcking, impairing P2X7R expression in the
plasma membrane. In this context, it is reasonable to assume
that under our experimental conditions, LPS is binding to
its putative site in the P2X7R, interfering with the normal
traﬃcking and assemblage of the receptor in the cell surface.
This mechanism could explain the gradual decrease in
currents and calcium transients as well as the inhibition
of BrEt uptake that we observed after LPS application to
P2X7R-HEK293 cells. Ongoing experiments in our lab will
address this possibility in future works.
Although a direct interaction of LPS with the P2X7R
seems the most reasonable mechanism, it is also possible
that LPS eﬀects are indirect and mediated by proteinsMediators of Inﬂammation 9
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other than TLRs [35]. These putative targets include the
activation of the inﬂammasome (in codependence of P2Xs
andTLRsactivation[36])andcouldberelatedtotheP2X7R-
pannexin-1 complex, caspase activation, and production of
inﬂammatory mediators [37, 38]. Ectonucleotidase inhibi-
tion by LPS [39–41] does not seem to be involved under
our experimental conditions; it has been demonstrated that
ATP degradation appears to be lower and not signiﬁcant
[14]. The possibility cannot be excluded that LPS could
interact directly with ATP, decreasing its free concentration.
However, there is extensive evidence that lipids can modulate
the P2X7R, either positively or negatively (as allosteric po-
tentiators or inhibitors), suggesting that these molecules
could interact directly with receptor regions and thereby
exert their modulatory eﬀect[13–16]. It would be interesting
to determine how subtle modiﬁcations in lipid structure
aﬀect P2X7R. Future investigations will help to clarify this
and determine structure-activity relationships, including
possible studies with other LPS serotypes.
In our hands, LPS inhibited P2X7R activity when cells
were pre-treated with LPS. In microglial cells, LPS had
no signiﬁcant eﬀect on P2X7R-mediated currents although
Raoufetal.observedatendencyforcurrentstodecrease[42].
The apparent discrepancy between this study and our work
could be explained by the fact that the electrophysiological
recordings of Raouf et al. were performed in the absence
of serum [42]. How LPS exerts its eﬀects on cells is not
clear. LPS has a complex pattern to induce cell activation,
including several pathways for cell entry. Its internalization,
which is energy-dependent [43], includes clathrin-coated
vesicles [44–48], macropinocytosis [49], noncoated plasma
membraneinvaginations[43],andalsooccursbynonspeciﬁc
endocytosis. Once inside the cell, LPS has been detected
in endosomes, phagosomes, lysosomes, the golgi complex10 Mediators of Inﬂammation
[44–48], and the cytoplasm [50, 51]. However, the mecha-
nism by which LPS passes through the plasma membrane of
the cell is unknown.
In our study, we consistently found that FBS increases
the amplitude of ATP-induced currents. Although we did
not study this point in detail, we can infer that serum
components, such as cytokines, growth factor, and other
proteins are responsible for this eﬀect. Previously, Michel et
al.reportedthatserum,andspeciﬁcallyalbumin,couldaﬀect
the aﬃnity of P2X7R for BzATP, measured as ethidium bro-
mide uptake [14]. Recently 2 immune compounds have been
identiﬁedasP2X7Ractivators.Serumamyloidprotein(SAA)
can induce the expression of pro-IL-1β and activation of the
NLRP3 inﬂammasome via P2X7R [52]. Similarly the human
cathelicidin-derived peptide LL37 induces maturation and
release of IL-1β via the P2X7R in LPS-primed monocytes
[53]. These compounds could be present in the serum and
potentially modify P2X7R activity. Another possibility is the
capacity for serum to chelate divalent cations, which are
known to inhibit the P2X7R. It would be highly relevant to
identify the serum component(s) responsible for the eﬀects
on the P2X7R and determine the mechanism that aﬀects
receptor activity.
The role of the P2X7R in regulatory mechanisms asso-
ciated with inﬂammation is well established. Ferrari et al.
were the ﬁrst to demonstrate that ATP potentiates post-
translational processing and the release of IL-1β from LPS
primed cells and that the P2X7R plays an important role in
this process [54]. This has further been supported by the
fact that P2X7R KO mice show a loss of ATP-dependent
immune functions [7, 55]. Moreover, P2X7R KO mice have
increased numbers of Foxp3-expressing CD4+ CD25+ cells
in the circulatory and lymphoid organs, indicating that
P2X7Rs may play a role in T-cell homeostasis [6, 56]. In
this regard, it has been demonstrated that P2X7R activation
leads to rapid cell death in a large proportion of the CD4+
CD25+ population, without signiﬁcantly aﬀecting other T
cell populations [24]. In their study, Perregaux and Gabel
argued that these dramatic diﬀerences in sensitivity among
T cells appear to be related to the presence of the P2X7R
[57], in agreement with our results. Gene array analyses
indicate higher expression of P2X7Rs in Treg cells compared
to conventional T-eﬀector cells [58] and cell sensitivity in
cells, and mouse strain shows a correlation with P2X7R
surface expression [59]. In this context, large amounts of
ATP can be highly deleterious, leading to the induction of
apoptosis, impairing inﬂammatory and immune response.
Given that P2X7R ligands can also inﬂuence LPS-stimulated
IL-β release, ion ﬂuxes, phospholipase and transcription
factor activation, protein kinase cascades, and apoptosis, the
regulation among those activities should be ﬁne-tuned.
In summary, our results provide evidence for the physio-
logicalrelevanceofLPSasamodulatoroftheP2X7Rthrough
its putative intracellular binding site. This process could be
relevant during inﬂammatory or infectious processes, where
extracellular ATP availability is high and/or maintained
over time. The presence of LPS under these conditions
could favor signal transduction instead of channel activation
and apoptosis, leading to a more eﬃcient response against
pathogens.
Acknowledgments
The authors thank Dr. Stanko Stojilkovic and Dr. Andr´ es
Stutzin for the critical review of this paper, Dra Marcela
HermosoforTLR-4antibody, Dr.JaimeEugeninforA74003,
Manuela Jimenez, Felipe Reyes, Belgica Villegas, Yohana
Labra, Carolina Beltran, and Gino Nardocci for technical
assistance. This work was funded by FONDECYT 11070117,
DICYT USACH, and PBCT. A.Penna and E. leiva. Salcedo
were funded by the Center for Molecular Studies of the
Cell, FONDAP 15010006. C.Coddou was funded by the
Intramural Research Program of the National Institutes
of Health National Institute of Child Health and Human
Development. J. P. Huidobro-Toro was supported by the
J. V. Luco Center for Cell Regulation and Pathology; the
Millennium Institute for Fundamental and Applied Biology
(MIFAB)alsocontributed to the Center’s funding. This work
is in memory of Alfonso Salinas, Ricardo Castillo and Ruth
Quiroz I. Special thanks go to Mr. George Montgomery for
proofreading the paper. E. Leiva-Salcedo, C. Coddou, and
F. E. Rodr´ ıguez contributed equally to this work.
References
[1] F. Koch-Nolte, F. Haag, A. H. Guse, F. Lund, and M.
Ziegler, “Emerging roles of NAD+ and its metabolites in cell
signaling,” Science Signaling, vol. 2, no. 57, p. mr1, 2009.
[2] F. Haag, S. Adriouch, A. Braß et al., “Extracellular NAD
and ATP: partners in immune cell modulation,” Purinergic
Signalling, vol. 3, no. 1-2, pp. 71–81, 2007.
[3] R. A. North, “Molecular physiology of P2X receptors,” Physio-
logical Reviews, vol. 82, no. 4, pp. 1013–1067, 2002.
[4] A. Surprenant and R. Alan North, “Signaling at purinergic
P2X receptors,” Annual Review of Physiology, vol. 71, pp. 333–
359, 2009.
[5] P. Pelegrin and A. Surprenant, “Pannexin-1 mediates large
pore formation and interleukin-1β release by the ATP-gated
P2X7 receptor,” EMBO Journal, vol. 25, no. 21, pp. 5071–5082,
2006.
[6] L. Chen and C. F. Brosnan, “Regulation of immune response
by P2X7 receptor,” CriticalReviewsinImmunology,vol.26,no.
6, pp. 499–513, 2006.
[7] J. M. Labasi, N. Petrushova, C. Donovan et al., “Absence of
the P2X7 receptor alters leukocyte function and attenuates an
inﬂammatory response,” Journal of Immunology, vol. 168, no.
12, pp. 6436–6445, 2002.
[8] F. Di Virgilio, “Liaisons dangereuses: P2X7 and the inﬂamma-
some,” Trends in Pharmacological Sciences,v o l .2 8 ,n o .9 ,p p .
465–472, 2007.
[9] L. Franchi, T. Eigenbrod, R. Mu˜ noz-Planillo, and G. Nu˜ nez,
“The inﬂammasome: a caspase-1-activation platform that
regulatesimmuneresponsesanddiseasepathogenesis,”Nature
Immunology, vol. 10, no. 3, pp. 241–247, 2009.
[10] C. Acu˜ na-Castillo, C. Coddou, P. Bull, J. Brito, and J. P.
Huidobro-Toro, “Diﬀerential role of extracellular histidines in
copper, zinc, magnesium and proton modulation of the P2X7
purinergic receptor,” Journal of Neurochemistry, vol. 101, no.
1, pp. 17–26, 2007.Mediators of Inﬂammation 11
[11] C. Virginio, D. Church, R. A. North, and A. Surprenant,
“Eﬀects of divalent cations, protons and calmidazolium at the
rat P2X7 receptor,” Neuropharmacology, vol. 36, no. 9, pp.
1285–1294, 1997.
[12] T. Takenouchi, M. Sato, and H. Kitani, “Lysophosphatidyl-
choline potentiates Ca2+ inﬂux, pore formation and p44/42
MAPkinase phosphorylation mediated by P2X7 receptor acti-
vation in mouse microglial cells,” Journal of Neurochemistry,
vol. 102, no. 5, pp. 1518–1532, 2007.
[13] Q. Zhao, M. Yang, A. T. Ting, and D. E. Logothetis, “PIP(2)
regulates the ionic current of P2X receptors and P2X(7)
receptor-mediated cell death,” Channels (Austin, Tex.), vol. 1,
no. 1, pp. 46–55, 2007.
[14] A. D. Michel, M. Xing, and P. Humphrey, “Serum constituents
can aﬀect 2 -& 3 -O-(4-benzoylbenzoyl)-ATP potency at
P2X7 receptors,” British Journal of Pharmacology, vol. 132, no.
7, pp. 1501–1508, 2001.
[15] R. Barbieri, S. Alloisio,S. Ferroni, and M.Nobile, “Diﬀerential
crosstalk between P2X7 and arachidonic acid in activation of
mitogen-activated protein kinases,” Neurochemistry Interna-
tional, vol. 53, no. 6–8, pp. 255–262, 2008.
[16] D. Ferrari, C. Pizzirani, E. Adinolﬁ et al., “The antibiotic
p o l y m y x i nBm o d u l a t e sP 2 X 7r e c e p t o rf u n c t i o n , ”Journal of
Immunology, vol. 173, no. 7, pp. 4652–4660, 2004.
[17] A. D. Michel and E. Fonfria, “Agonist potency at P2X7
receptors is modulated by structurally diverse lipids,” British
Journal of Pharmacology, vol. 152, no. 4, pp. 523–537, 2007.
[18] E. Alzola, A. P´ erez-Etxebarria, E. Kabr´ e et al., “Activation
by P2X7 agonists of two phospholipases A2 (PLA2) in
ductal cells of rat submandibular gland: coupling of the
calcium-independent PLA2 with kallikrein secretion,” Journal
of Biological Chemistry, vol. 273, no. 46, pp. 30208–30217,
1998.
[19] M. A. Balboa, J. Balsinde, D. A. Dillon, G. M. Carman, and E.
A. Dennis, “Proinﬂammatory macrophage-activating proper-
ties of the novel phospholipid diacylglycerol pyrophosphate,”
Journal of Biological Chemistry, vol. 274, no. 1, pp. 522–526,
1999.
[20] L.C.Denlinger,P.L.Fisette,J.A.Sommeretal.,“Cuttingedge:
the nucleotide receptor P2X7 contains multiple protein- and
lipid-interaction motifs including a potential binding site for
bacterial lipopolysaccharide,” Journal of Immunology, vol. 167,
no. 4, pp. 1871–1876, 2001.
[21] S. Li, H. Lu, X. Hu, W. Chen, Y. Xu, and J. Wang, “Expression
of TLR4-MyD88 and NF-B in the iris during endotoxin-
induced uveitis,” Mediators of Inﬂammation, vol. 2010, Article
ID 748218, 7 pages, 2010.
[22] C. Acu˜ na-Castillo, M. Aravena, E. Leiva-Salcedo et al., “T-
kininogen, a cystatin-like molecule, inhibits ERK-dependent
lymphocyte proliferation,” Mechanisms of Ageing and Devel-
opment, vol. 126, no. 12, pp. 1284–1291, 2005.
[23] R. Fern´ andez, G. Nardocci, F. Simon et al., “Lipopolysac-
charide signaling in the carotid chemoreceptor pathway
of rats with sepsis syndrome,” Respiratory Physiology and
Neurobiology, vol. 175, no. 3, pp. 336–348, 2011.
[24] F. Aswad, H. Kawamura, and G. Dennert, “High sensitivity
of CD4+CD25+ regulatory T cells to extracellular metabolites
nicotinamide adenine dinucleotide and ATP: a role for P2X7
receptors,” Journal of Immunology, vol. 175, no. 5, pp. 3075–
3083, 2005.
[25] E. M. P˚ alsson-McDermott and L. A. J. O’Neill, “Signal trans-
duction by the lipopolysaccharide receptor, Toll-like receptor-
4,” Immunology, vol. 113, no. 2, pp. 153–162, 2004.
[26] R.Auger,I.Motta,K.Benihoud,D.M.Ojcius,andJ.M.Kanel-
lopoulos, “A role for mitogen-activated protein kinaseErk1/2
activationandnon-selectiveporeformationinP2X7receptor-
mediated thymocyte death,” Journal of Biological Chemistry,
vol. 280, no. 30, pp. 28142–28151, 2005.
[27] D. L. Donnelly-Roberts, M. T. Namovic, C. R. Faltynek, and
M. F. Jarvis, “Mitogen-activated protein kinase and caspase
signaling pathways are required for P2X7 receptor (P2X7R)-
induced pore formation in human THP-1 cells,” Journal of
Pharmacology and Experimental Therapeutics, vol. 308, no. 3,
pp. 1053–1061, 2004.
[28] R. X. Faria, F. P. DeFarias, and L. A. Alves, “Are second
messengers crucial for opening the pore associated with P2X 7
receptor?” American Journal of Physiology, vol. 288, no. 2, pp.
C260–C271, 2005.
[ 2 9 ]L .P a p p ,E .S .V i z i ,a n dB .S p e r l´ agh, “P2X7 receptor mediated
phosphorylation of p38MAP kinase in the hippocampus,”
Biochemical and Biophysical Research Communications, vol.
355, no. 2, pp. 568–574, 2007.
[30] P. A. Verhoef, M. Estacion, W. Schilling, and G. R. Dubyak,
“P2X7 receptor-dependent blebbing and the activation of
Rho-eﬀector kinases, caspases, and IL-1β release,” Journal of
Immunology, vol. 170, no. 11, pp. 5728–5738, 2003.
[31] J. Amstrup and I. Novak, “P2X7 receptor activates extracellu-
lar signal-regulated kinases ERK1 and ERK2 independently of
Ca2+ inﬂux,” Biochemical Journal, vol. 374, no. 1, pp. 51–61,
2003.
[32] M.Garcia-Marcos,E.P´ erez-Andr´ es,S.Tandeletal.,“Coupling
of two pools of P2X7 receptors to distinct intracellular
signaling pathways in rat submandibular gland,” Journal of
Lipid Research, vol. 47, no. 4, pp. 705–714, 2006.
[33] M. Garcia-Marcos, S. Pochet, A. Marino, and J. P. Dehaye,
“P2X7 and phospholipid signalling: the search of the “missing
link” in epithelial cells,” Cellular Signalling, vol. 18, no. 12, pp.
2098–2104, 2006.
[34] L. C. Denlinger, J. A. Sommer, K. Parker et al., “Mutation of a
dibasic amino acid motif within the C terminus of the P2X7
nucleotide receptor results in traﬃcking defects and impaired
function,” Journal of Immunology, vol. 171, no. 3, pp. 1304–
1311, 2003.
[35] G. J. Brunn and J. L. Platt, “The etiology of sepsis: turned
inside out,” Trends in Molecular Medicine,v o l .1 2 ,n o .1 ,p p .
10–16, 2006.
[36] A. Babelova, K. Moreth, W. Tsalastra-Greul et al., “Biglycan,
a danger signal that activates the NLRP3 inﬂammasome via
toll-like and P2X receptors,” Journal of Biological Chemistry,
vol. 284, no. 36, pp. 24035–24048, 2009.
[37] C. A. Dinarello, “A signal for the caspase-1 inﬂammasome free
of TLR,” Immunity, vol. 26, no. 4, pp. 383–385, 2007.
[38] T. D. Kanneganti, M. Lamkanﬁ, Y. G. Kim et al., “Pannexin-
1-mediated recognition of bacterial molecules activates the
cryopyrin inﬂammasome independent of Toll-like receptor
signaling,” Immunity, vol. 26, no. 4, pp. 433–443, 2007.
[39] R. W. S. Li, R. Y. K. Man, P. M. Vanhoutte, and G. P. H. Leung,
“Stimulation of ecto-5 -nucleotidase in human umbilical vein
endothelial cells by lipopolysaccharide,” American Journal of
Physiology, vol. 295, no. 3, pp. H1177–H1181, 2008.
[40] R. Utili, C. O. Abernathy, and H. J. Zimmerman, “Inhibition
of Na+, K+-adenosinetriphosphatase by endotoxin: a possible
mechanism for endotoxin-induced cholestasis,” Journal of
Infectious Diseases, vol. 136, no. 4, pp. 583–587, 1977.
[ 4 1 ]F .C .V u a d e n ,G .d eP a u l aC o g n a t o ,C .B o n o r i n o ,M .R .B o g o ,
J. J. de Freitas Sarkis, and C. D. Bonan, “Lipopolysaccharide12 Mediators of Inﬂammation
alters nucleotidase activities from lymphocytes and serum of
rats,” Life Sciences, vol. 80, no. 19, pp. 1784–1791, 2007.
[42] R.Raouf,A.J.Chabot-Dor´ e,A.R.Ase,D.Blais,andP.S´ egu´ ela,
“Diﬀerential regulation of microglial P2X4 and P2X7 ATP
receptors following LPS-induced activation,” Neuropharma-
cology, vol. 53, no. 4, pp. 496–504, 2007.
[43] R. L. Kitchens and R. S. Munford, “CD14-dependent inter-
nalization of bacterial lipopolysaccharide (LPS) is strongly
inﬂuenced by LPS aggregation but not by cellular responses to
LPS,” Journal of Immunology, vol. 160, no. 4, pp. 1920–1928,
1998.
[44] J. A. Gegner, R. J. Ulevitch, and P. S. Tobias, “Lipopolysac-
charide (LPS) signal transduction and clearance. Dual roles
for LPS binding protein and membrane CD14,” Journal of
Biological Chemistry, vol. 270, no. 10, pp. 5320–5325, 1995.
[45] R. Y. Hampton, D. T. Golenbock, M. Penman, M. Krieger,
and C. R. H. Raetz, “Recognition and plasma clearance of
endotoxin by scavenger receptors,” Nature, vol. 352, no. 6333,
pp. 342–344, 1991.
[46] Y. H. Kang, R. S. Dwivedi, and C. H. Lee, “Ultrastructural and
immunocytochemical study of the uptake and distribution of
bacterial lipopolysaccharide in human monocytes,” Journal of
Leukocyte Biology, vol. 48, no. 4, pp. 316–332, 1990.
[47] J. Kriegsmann, S. Gay, and R. Br¨ auer, “Endocytosis of
lipopolysaccharide in mouse macrophages,” Cellular and
Molecular Biology, vol. 39, no. 7, pp. 791–800, 1993.
[48] N. Thieblemont and S. D. Wright, “Transport of bacterial
lipopolysaccharide to the Golgi apparatus,” Journal of Exper-
imental Medicine, vol. 190, no. 4, pp. 523–534, 1999.
[49] C. Poussin, M. Foti, J. L. Carpentier, and J. Pugin, “CD14-
dependent endotoxin internalization via a macropinocytic
pathway,” Journal of Biological Chemistry, vol. 273, no. 32, pp.
20285–20291, 1998.
[50] Y .H.K ang,C.H.Lee,R.L.M onr o y ,R.S.Dwi v edi,C.Odeyale,
and H. H. Newball, “Uptake, distribution and fate of bacterial
lipopolysaccharides in monocytes and macrophages: an ultra-
structural and functional correlation,” Electron Microscopy
Reviews, vol. 5, no. 2, pp. 381–419, 1992.
[51] G. D. Kutuzova, R. M. Albrecht, C. M. Erickson, and
N. Qureshi, “Diphosphoryl lipid A from Rhodobacter
sphaeroides blocks the binding and internalization of
lipopolysaccharide in RAW 264.7 cells,” Journal of Immunol-
ogy, vol. 167, no. 1, pp. 482–489, 2001.
[52] K. Niemi, L. Teiril¨ a, J. Lappalainen et al., “Serum amyloid A
activates the NLRP3 inﬂammasome via P2X7 receptor and a
cathepsin B-sensitive pathway,” Journal of Immunology, vol.
186, no. 11, pp. 6119–6128, 2011.
[53] A. Elssner, M. Duncan, M. Gavrilin, and M. D. Wewers, “A
novelP2X7receptoractivator,thehumancathelicidin-derived
peptideLL37,inducesIL-1β processingandrelease,”Journalof
Immunology, vol. 172, no. 8, pp. 4987–4994, 2004.
[54] D. Ferrari, P. Chiozzi, S. Falzoni et al., “Extracellular ATP
triggersIL-1β releasebyactivatingthepurinergicP2Zreceptor
of human macrophages,” Journal of Immunology, vol. 159, no.
3, pp. 1451–1458, 1997.
[55] I.P.Chessell,J.P.Hatcher,C.Bountraetal.,“Disruptionofthe
P2X7 purinoceptor gene abolishes chronic inﬂammatory and
neuropathic pain,” Pain, vol. 114, no. 3, pp. 386–396, 2005.
[ 5 6 ]L .C h e na n dC .F .B r o s n a n ,“ E x a c e r b a t i o no fe x p e r i m e n t a l
autoimmune encephalomyelitis in P2X 7R−/− mice: evidence
for loss of apoptotic activity in lymphocytes,” Journal of
Immunology, vol. 176, no. 5, pp. 3115–3126, 2006.
[57] D. G. Perregaux and C. A. Gabel, “Post-translational process-
ing of murine IL-1: evidence that a tp- induced release of
IL-1α and IL-1β occurs via a similar mechanism,” Journal of
Immunology, vol. 160, no. 5, pp. 2469–2477, 1998.
[58] A. E. Herman, G. J. Freeman, D. Mathis, and C. Benoist,
“CD4+CD25+ T regulatory cells dependent on ICOS promote
regulation of eﬀector cells in the prediabetic lesion,” Journal of
Experimental Medicine, vol. 199, no. 11, pp. 1479–1489, 2004.
[59] F. Aswad and G. Dennert, “P2X7 receptor expression levels
determine lethal eﬀects of a purine based danger signal in T
lymphocytes,” Cellular Immunology, vol. 243, no. 1, pp. 58–65,
2006.